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The Need for Secondary
Prevention of Suicide
Suicide poses major threats to public
health worldwide. In 2002, suicide ac-
counted for about 30,000 deaths in the US
alone [1] and approximately 877,000
deaths worldwide—1.5% of the global
burden of disease [2]. Suicide should and
can be prevented. 83% of people who
commit suicide have had contact with a
primary care physician within a year of
their death and up to 66% of people who
commit suicide have had such contact
within a month of their death [3].
Suicidal behavior has been conceptual-
ized as a continuum of thoughts and
behaviors ranging from suicidal ideation
to completed suicide. Recent retrospective
research delineates seven distinct catego-
ries of ‘‘suicidality’’: (1) completed suicide,
(2) suicide attempt, (3) preparatory acts
toward imminent suicidal behavior, (4)
suicidal ideation, (5) self-injurious behavior
without intent to die, (6) nondeliberate
self-harm, and (7) self-harm behavior with
unknown suicidal intent [4].
Suicide prevention can be primary,
secondary, or tertiary. Primary suicide
prevention aims to reduce the number of
new cases of suicide in the general popu-
lation [5]. Secondary suicide prevention
aims to decrease the likelihood of a suicide
attempt in high-risk patients [5]. Tertiary
suicide prevention occurs in response to
completed suicides and attempts to dimin-
ish suicide contagion (clusters of suicides in
a geographical area that occur predomi-
nantly among teenagers and young adults)
and copy-cat suicides [5,6].
Secondary suicide prevention is partic-
ularly important but not always given the
attention that it deserves, in part because
research into secondary prevention is only
just starting to be applied to clinical
practice. In this article, we discuss recent
research on the evaluation of suicidal risk
and on different kinds of secondary suicide
prevention interventions that aim to re-
duce that risk. We also indicate how these
interventions are currently being applied
and what additional research is needed.
Clinical Evaluation of Suicide
Risk
Suicide is often difficult to predict due to
its complex nature [7,8]. Some of the risk
factors that contribute to suicidal behavior
are shown in Box 1 [1,5,9–11]. Research
shows that these suicide risk factors are
additive but can be divided into underly-
ing causes such as biological and psycho-
logical factors, and more proximal stress-
ors such as life events or a major
depressive episode (Box 1) [7,11]. Clini-
cians and others (termed gatekeepers by
Mann et al. [12]) dealing with individuals
who may be at risk for suicide should be
taught to recognize, assess, and address
such factors and to appropriately screen
at-risk patients for suicidality.
The clinical evaluation of the medical
and psychiatric history of a patient and of
their current state is the crucial and
essential element of the suicide assessment
process. This evaluation enables the clini-
cian to identify risk factors and protective
factors, to determine the patient’s imme-
diate safety and the best setting for
treatment, and to develop a differential
diagnosis and treatment strategies.
Psychiatric illness is a major contributing
factor to suicide risk, with mood disorders
such as major depressive disorder and
bipolar disorder being associated with
about 60% of suicides [12–14]. Indeed,
psychiatric disorders are diagnosed in more
than 90% of completed suicides, and more
than 80% of these disorders are untreated
at the time of death [13,14]. Thus, the
recognition and treatment of individuals
with psychiatric disorders, specifically
mood disorders, are essential components
of secondary suicide prevention. In addi-
tion, the subjective rating of the severity of
depression is one of the most powerful
predictors of future suicidal acts [11].
Therefore, assessing and managing depres-
sion as well as being aware of the suicide
risks in psychologically, medically, and
neurologically disordered individuals is an
important aspect of secondary suicide
prevention [11]. Consequently, physicians
need to be taught to recognize depression
and to be educated about the association
between mental disorders and suicide.
Additional information about the individ-
u a lw h om a yb ea tr i s kf o rs u i c i d e ,s u c ha s
depositions, medical and psychiatric treat-
ment records, and toxicology screenings,
should also be incorporated into the assess-
ment. Additional information of this sort
may be especially helpful, because informa-
tion from individuals with mood disorders,
borderline traits, or psychosis can be unre-
liable. Interviews with friends and relatives
may also be helpful in assessing suicide risk.
Equally importantly, clinicians and oth-
er professionals in a position to offer help
should not hesitate to ask patients about
suicidal ideation because, while it may
seem surprising, patients will often talk
frankly about their suicidal thoughts and
tendencies if given the opportunity. Fail-
ure to ask about suicidal ideation may be
related to the care provider’s discomfort
with the topic, lack of time, or lack of skills
in this area. Clinicians need to overcome
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to their patients.
A final component of the clinical assess-
ment of suicide risk is the gathering of
information about current and past suicidal
ideationandbehavior, andaboutpsychiatric
conditions associated with suicidal behavior.
There are many self-report and clinician-
administered scales that measure different
aspects of suicidal behavior or mental health
conditions related to it (Box 2) [15–20].
Although these scales are reliable and have
adequate concurrent validity, at present they
are more useful as research tools than in the
clinical setting, because they are limited in
their assessment of comorbid risk factors.
The Search for Biological
Markers for Suicide
Many researchers have been trying to
find biological markers related to suicidal
behavior that could improve secondary
suicide prevention. Several biological fea-
tures related to failures in neurotransmitter
and neuroendocrine systems, such as the
serotonergic, noradrenergic, dopaminergic,
and hypothalamic-pituitary-adrenocortical
(HPA) systems, have been proposed
[21,22]. For example, considerable evi-
dence accrued using various research
approaches suggests a potentially causal
association between suicidal behavior and
the serotonin neurotransmission system
[21–23]. Similarly, there is some evidence
that dysregulation of HPA axis function
may be involved in suicidal behavior in the
contextofacutestressresponsetolifeevents
[24,25]. In particular, nonsuppression of
the HPA axis by dexamethasone is associ-
ated with a 14-fold increase in the likeli-
hood ofsuicide during15 years offollow-up
[25]. Finally, postmortem analyses of the
noradrenergic system, which has been
studied because it is involved in the
regulation of the stress response, have
revealed fewer noradrenergic neurons in
the locus coeruleus, elevated brainstem
levels of tyrosine hydroxylase, and reduced
levels of postsynaptic adrenergic receptors
in the cortex in people who commit suicide
compared to the general population [24].
However, these findings may be related to
an increased stress response before suicide
rather than being a cause of suicide.
To date, the most promising biological
predictors of suicidal behavior are low
cerebrospinal fluid 5-hydroxyindoleacetic
acid (5-HIAA, the main serotonin metab-
olite) and HPA axis dysregulation as
indicated by dexamethasone nonsuppres-
sion [25,26]. However, none of the
putative biological markers identified to
date are sensitive or precise enough to
recommend their routine use in the
clinical setting; additional translational
and clinical studies are needed to under-
stand the complex brain–mind relation-
ship involved in suicidal behaviors.
What Are the Most Effective
Secondary Suicide Prevention
Strategies?
In a recent systematic review of suicide
prevention strategies, Mann et al. [12],
found evidence of effectiveness in five
secondary suicide prevention methods:
pharmacological interventions, psycholog-
ical interventions, follow-up care, reduced
access to lethal means, and responsible
media reporting of suicide [12].
Box 1. Risk Factors for Suicide
Biological risk factors for suicide include:
N Low cerebrospinal fluid 5-hydroxyindolacetic acid levels
N Hypothalamic-pituitary-adrenal axis dysregulation
N Low blood cholesterol levels
N Medical or neurological illnesses (such as multiple sclerosis, stroke, Huntington
disease, and epilepsy)
N Cigarette smoking
Psychological risk factors include:
N Acceptability of suicide
N A childhood history of physical or sexual abuse





N Poor access to psychiatric treatment
More proximal stressors that indicate an increased suicide risk include:
N Relationship problems
N Financial troubles
N A family or personal history of suicide
N Major depression
N Substance use
Box 2. Rating Scales for Suicide Behavior and Related Mental
Health Conditions
The most widely used scales for rating suicidal behaviors include:
N The Scale for Suicidal Ideation [15] has good reported reliability and validity and
measures three major factors: active suicidal desire, specific plans for suicide,
and passive suicidal desire.
N The Suicide Intent Scale [16] measures the degree of suicide intent.
N The Risk-Rescue Rating Scale [17] is an interviewer-administered measure that
assesses the lethality and intent of a suicide attempt.
N The Columbia-Suicide Severity Rating Scale [4] assesses severity of suicidal
ideation and tracks suicidal events.
N The Beck Hopelessness Scale [18] is a self-report inventory designed to measure
three major aspects of hopelessness: feelings about the future, loss of
motivation, and expectations.
N The Hamilton Depression Rating Scale [19] is a clinician-applied scale rating
dimensions of depression.
N The Beck Depression Inventory [20] is a multiple-choice self-report inventory
that measures the severity of depression.
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most widely used pharmacological inter-
ventions in secondary suicide prevention,
but studies of their effectiveness in reduc-
ing suicide attempts and completed sui-
cides have had mixed results [12]. For
example, although population studies
show a decrease in suicide rates in the 27
countries with the greatest increase in
selective serotonin reuptake inhibitor
(SSRI) prescription [27], in 2003 and
2004 US and European regulators issued
warnings about a possible association
between antidepressant use and suicidal
thinking and behavior. Since then, a meta-
analysis [28] of randomized controlled
trials has suggested that SSRIs may
increase suicide ideation compared with
placebo, but observational studies have
suggested that SSRIs do not increase
suicide risk any more than older antide-
pressants. If SSRIs do increase suicide risk
in some patients, the number of additional
deaths must be very small because ecolog-
ical studies have generally found that
suicide mortality has declined (or at least
not increased) as SSRI use has increased.
Moreover, Gibbons et al. [29] recently
reported that, although SSRI prescriptions
for children and adolescents decreased in
both the US and The Netherlands after
warnings were issued about a possible
suicide risk with antidepressant use in
pediatric patients, these decreases in SSRI
use were associated with increases in
suicide rates in children and adolescents.
A US Food and Drug Administration
study recently reported that the risk of
suicidality associated with use of antide-
pressants is age dependent [30]. Compared
with placebo, the increased risk for suicid-
ality and suicidal behavior among adults
younger than 25 taking antidepressants
approaches that observed in children and
adolescents. The effect of antidepressants
seemstobeneutralonsuicidal behaviorbut
possibly protective for suicidal ideation in
adults aged 25–64 and seems to reduce the
riskofbothsuicidalityand suicidalbehavior
in the elderly. Thus, the relation between
antidepressants and suicidality needs fur-
ther studies before this class of drugs (SSRIs
in particular) can be safely used for the
secondary prevention of suicide.
In terms of psychological interventions,
suicidal patients often benefit from thera-
pies that address the repetition of suicidal
thoughts and behaviors, treatment adher-
ence, and other factors commonly associ-
ated with suicidality [31–36]. Cognitive
therapy decreases both suicidal ideation
and the reattempt rate of past suicide
attempters [31], and intensive care plus
outreach and interpersonal psychotherapy
decrease suicidal ideation [32]. In border-
line personality disorder, which is associ-
ated with suicidality [37], dialectical be-
havioral therapy (which teaches patients
how to reverse their negative thoughts and
behaviors) and partial hospitalization in a
psychoanalytically oriented facility im-
prove treatment adherence and reduce
suicidal behavior more than standard
after-care [33]. Problem-solving therapy
works to improve the mediating factors of
suicidality; such as hopelessness and de-
pression [32]. Better psychological and
pharmacological treatment of depression
and alcoholism, even in the absence of
overt suicidal thoughts or behaviors, also
appears to decrease suicide rates [5,7,10].
Follow-up care to maintain adherence to
therapy (in particular, antidepressant use)
after suicide attempts is also an effective
approach to secondary suicide prevention
[12]. Follow-up care can be provided by a
case manager or by psychiatric hospitaliza-
tion when appropriate [34]. Social factors
that should be addressed in follow-up
treatment include availability and willing-
ness of supports within the family, within a
facility, or by a support person designated
to monitor the at-risk person. Support
individuals who should be contacted about
the suicide risk and follow-up arrangements
include general practitioners, private psy-
chiatrists, case managers, family, and
friends. Regions that provide such follow-
up care have lower treatment dropout rates
and fewer repeat suicide attempts [36].
Some interventions, however, such as
telephone and psychosocial follow-up, have
shown no difference in reattempt rate and
suicidal ideation when compared with
standard after-care [12].
Many studies show that suicides by
particular methods (for example, firearms,
domestic gas, or pesticides) decrease after the
introduction of legal restrictions that reduce
access to such means [12]. This reduction in
suicide rates is particularly influential in
regions where the specific means restriction
correlates with a common method of suicide
[25,26,38,39]. For example, in the UK the
reduction of the mean percentage of carbon
monoxide in domestic gassince 1958 and the
reduced availability of analgesics since the
mid-1990s have both decreased UK suicide
rates [39]. Although method substitution is
possible, such results show that the restriction
of lethal means can save lives, mainly by
decreasing the acute risk of suicide, which is
related to impulsive suicidal behaviors.
Finally, many studies have exposed a
need for a decrease in reporting of suicide
and for responsible reporting. Media black-
outs in reporting suicide have coincided
with a decrease in suicide rates [40],
possibly because reports of suicide in the
media present suicide as a viable solution to
life’s problems and/or glamorize suicide for
vulnerable individuals [41]. The Internet is
also of increasing concern, with blogs and
chatroomssocializingsuicideandproviding
accessible instructions for suicide [42]. For
these reasons, guidelines have recently been
produced for the responsible reporting of
suicide [12,43]. However, the efficacy of
these guidelines has not yet been assessed.
The Future of Secondary
Suicide Prevention
Despite our increasing knowledge about
secondary suicide prevention, there are
still many gaps in the research. The
prescription of SSRIs and their impact
on suicidal inclinations, especially in
depressed children and adolescents, re-
main hotly debated topics [44]. Similarly,
the most effective combinations of psycho-
therapeutic and pharmacologic interven-
tions for suicidal patients have yet to be
determined. And, while follow-up care has
proven an effective element of suicide
prevention, exactly which interventions
are most effective remains unclear.
Nevertheless, much of what we have
learnt about secondary suicide prevention
through research can now be applied to
the real world. For example, we know that
to provide the best secondary suicide
prevention, clinicians must learn how to
evaluate at-risk individuals properly. We
know that after completing these assess-
ments, clinicians can now use well-re-
searched psychological and pharmacolog-
ical methods to decrease the levels of
suicidality in their patients. We know that
legally restricting access to lethal means
and responsible media reporting of suicide
correlate with a decrease in suicides
worldwide [12]. And we know that the
education of clinicians and society at large
about suicide prevention is crucial.
Looking to the future, thorough evalu-
ations and appropriate treatments of
patients with depressive disorders and
other psychiatric illnesses should help to
improve the efficacy of secondary preven-
tion of suicide. But, it is also clear that
more research into new approaches for the
prevention and treatment of suicidal
behavior remains essential.
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